1. Home
  2. ABLV vs SCYX Comparison

ABLV vs SCYX Comparison

Compare ABLV & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

HOLD

Current Price

$0.92

Market Cap

39.9M

Sector

N/A

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$3.66

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
SCYX
Founded
2015
1999
Country
China
United States
Employees
164
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
42.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ABLV
SCYX
Price
$0.92
$3.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
65.2K
82.7K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
$16.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.57
52 Week High
$1.77
$5.62

Technical Indicators

Market Signals
Indicator
ABLV
SCYX
Relative Strength Index (RSI) 34.37 42.77
Support Level $0.91 $0.66
Resistance Level $0.96 $5.10
Average True Range (ATR) 0.07 0.38
MACD -0.02 -0.16
Stochastic Oscillator 15.15 7.14

Price Performance

Historical Comparison
ABLV
SCYX

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: